文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

城市学术中心前列腺癌质子治疗利用的社会人口学差异

Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center.
PubMed 文献 · Adv Radiat Oncol · 2017-01-18

本研究回顾了2010至2015年间在单一城市学术中心接受根治性放疗的633例低、中危前列腺癌患者,比较质子治疗(PT)与调强放疗(IMRT)的使用差异。多变量分析显示,黑人及其他种族、距离、治疗年份和主诊医生与PT使用相关,而临床因素无关,提示存在社会人口学差异。

要点

  • 黑人患者接受PT的比值比显著低于白人(OR 0.29,95%CI 0.15-0.57)。
  • 居住地距离每增加1单位,PT使用比值比升高(OR 1.14,95%CI 1.06-1.24)。
  • 不同治疗年份和主诊医生与PT使用显著相关,提示非临床因素影响选择。

核心结论

  • 在城市学术机构中,前列腺癌质子治疗的使用存在社会人口学差异,需进一步研究可及性障碍以确保公平分配。

研究设计与样本

  • 单中心回顾性研究,纳入2010至2015年接受根治性放疗的低、中危前列腺癌患者633例,分为PT组508例和IMRT组125例,采用卡方检验、t检验及单/多因素logistic回归分析。

主要发现

  • IMRT组患者更年长(平均68 vs 66岁)、黑人比例更高(75% vs 51%)、居住地更近(平均距离21 vs 90英里)且更贫困(P<.05)。
  • IMRT组前列腺特异性抗原、前列腺体积和国际勃起功能指数显著更高(P<.05),但保险类型、风险分组、肿瘤分期、Gleason评分及患者报告泌尿肠道评分无显著差异(P>.05)。
  • PT组更常接受大分割治疗且较少接受雄激素剥夺治疗(P<.01)。
  • 多变量分析中,黑人(OR 0.29,95%CI 0.15-0.57)和其他种族(OR 0.42,95%CI 0.20-0.90)、距离(OR 1.14,95%CI 1.06-1.24)、治疗年份2011(OR 4.87,95%CI 2.23-10.6)、2012(OR 8.27,95%CI 3.43-19.9)、2014(OR 4.44,95%CI 1.94-10.2)及特定主诊医生(OR 0.38,95%CI 0.18-0.81)与PT使用相关,而临床因素不显著。

临床怎么用

  • 临床转诊质子治疗时需关注种族、居住距离和医生偏好等非临床因素可能导致的治疗选择差异。

局限性

  • 单中心回顾性设计可能限制结果的普遍性,且未分析的混杂因素可能影响结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite increasing use, proton therapy (PT) remains a relatively limited resource. The purpose of this study was to assess clinical and demographic differences in PT use for prostate cancer compared to intensity modulated radiation therapy (IMRT) at a single institution. METHODS AND MATERIALS: All patients with low- and intermediate-risk prostate cancer (N = 633) who underwent definitive radiation therapy between 2010 and 2015 were divided into PT (n = 508) and IMRT (n = 125) comparison groups and compared using χ2 and independent sample t tests. Univariable and multivariable logistic regression analyses were conducted to assess the associations between PT use and demographic, clinical, and treatment characteristics. RESULTS: The PT and IMRT cohorts varied by age, race, poverty, distance, treatment year, and treating physician. Patients who underwent IMRT were more likely to be older (mean age, 66 vs. 68 years), black (51% vs. 75%), and living in poverty or close to the facility (mean distance between residence and facility, 90 vs. 21 miles; P < .05). Prostate-specific antigen, prostate volume, and International Index of Erectile Function were significantly higher in the IMRT cohort (P < .05), but insurance type, risk group, tumor stage, Gleason score, and patient-reported urinary and bowel scores did not differ significantly (P > .05). Patients who underwent PT were more likely to receive hypofractionated therapy and less likely to receive androgen deprivation therapy (P < .01). On multivariable analysis, black (odds ratio [OR], 0.29; 95% confidence interval [CI], 0.15-0.57) and other race (OR, 0.42; 95% CI, 0.20-0.90); distance (OR, 1.14; 95% CI, 1.06-1.24); treatment years 2011 (OR, 4.87; 95% CI, 2.23-10.6), 2012 (OR, 8.27; 95% CI, 3.43-19.9), and 2014 (OR, 4.44; 95% CI, 1.94-10.2) relative to 2010; and a single treating physician (OR, 0.38; 95% CI, 0.18-0.81) relative to the reference physician with the highest rate of use were associated with PT use, whereas clinical factors such as prostate-specific antigen, prostate volume, International Index of Erectile Function, and androgen deprivation therapy were not. CONCLUSION: Sociodemographic disparities exist in PT use for prostate cancer at an urban academic institution. Further investigation of potential barriers to access is warranted to ensure equitable distribution across all demographic groups.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Woodhouse KD, Hwang WT, Vapiwala N, et al. Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center. Adv Radiat Oncol. 2017. PMID: 28740924. doi:10.1016/j.adro.2017.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。